Litcius/Paper detail

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas, Timothée Bruel, Ludivine Grzelak, Florence Guivel‐Benhassine, Isabelle Staropoli, Françoise Porrot, Cyril Planchais, Julian Buchrieser, Maaran Michael Rajah, Elodie Bishop, Mélanie Albert, Flora Donati, Matthieu Prot, Sylvie Behillil, Vincent Enouf, Marianne Maquart, Mounira Smati-Lafarge, Emmanuelle Varon, Frédérique Schortgen, Layla Yahyaoui, Maria Gonzalez, de Sèze, Hélène Péré, David Veyer, Aymeric Sève, Etienne Simon‐Lorière, Samira Fafi‐Kremer, Karl Stéfic, Hugo Mouquet, Laurent Hocqueloux, Sylvie van der Werf, Thiérry Prazuck, Olivier Schwartz

2021Nature Medicine776 citationsDOIOpen Access PDF

Topics & Concepts

AntibodySerologyVirologyTiterNeutralizing antibodyNeutralizationBiologyImmunologyVaccinationMedicineSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingCOVID-19 Clinical Research Studies
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies | Litcius